Adult Polyglucosan Body Disease: A Rare Presentation with Chronic Liver Disease and Ground-Glass Hepatocellular Inclusions

 

 Buy Article Permissions and Reprints

ABSTRACT

Liver involvement in genetic and metabolic disorders may result in intrahepatic accumulation of specific precursors or byproducts, which have distinctive features on light microscopy. The “polyglucosan disorders” are diseases in which polyglucosan (abnormal glycogen with decreased branching) is formed and deposited in various tissues because of decreased or absent glycogen branching enzyme activity. These disorders include Lafora disease (myoclonus epilepsy) and type IV glycogen storage disease. Polyglucosan deposits in both conditions result in ground-glass hepatocellular inclusions resembling those seen in chronic hepatitis B virus infection. In the present report, we describe a case of the rare, adulthood form of glycogen branching enzyme deficiency, adult polyglucosan body disease (APBD), in which abnormal serum liver tests prompted a liver biopsy. The pathologic findings of periportal ground-glass hepatocellular inclusions, mild chronic portal inflammation, and periportal fibrosis are not well described in APBD, but resemble the chronic changes that have been reported in Lafora disease. The differential diagnosis of ground-glass hepatocytes and the genetic basis of APBD are discussed.

REFERENCES

• 1 Portmann B C, Thompson R J, Roberts E A, Paterson A C. Genetic and metabolic liver disease. In: Burt A D, Portmann B C, Ferrell L D, eds. MacSween's Pathology of the Liver. 5th ed. Edinburgh: Elsevier; 2007: 199-326
  Google Scholar
• 2 Nishimura R N, Ishak K G, Reddick R, Porter R, James S, Barranger J A. Lafora disease: diagnosis by liver biopsy.  Ann Neurol. 1980;  8 (4) 409-415
  CrossrefPubMedGoogle Scholar
• 3 Suzuki K, David E, Kutschman B. Presenile dementia with “Lafora-like” intraneuronal inclusions.  Arch Neurol. 1971;  25 (1) 69-80
  CrossrefPubMedGoogle Scholar
• 4 Klein C J, Boes C J, Chapin J E et al.. Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome.  Muscle Nerve. 2004;  29 (2) 323-328
  CrossrefPubMedGoogle Scholar
• 5 Lossos A, Klein C J, McEvoy K M, Keegan B M. A 63-year-old woman with urinary incontinence and progressive gait disorder.  Neurology. 2009;  72 (18) 1607-1613
  CrossrefPubMedGoogle Scholar
• 6 Sindern E, Ziemssen F, Ziemssen T et al.. Adult polyglucosan body disease: a postmortem correlation study.  Neurology. 2003;  61 (2) 263-265
  CrossrefPubMedGoogle Scholar
• 7 Roe C R, Bottiglieri T, Wallace M, Arning E, Martin A. Adult polyglucosan body disease (APBD): anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways.  Mol Genet Metab. 2010;  101 (2-3) 246-252
  CrossrefPubMedGoogle Scholar
• 8 Hadziyannis S, Gerber M A, Vissoulis C, Popper H. Cytoplasmic hepatitis B antigen in “ground-glass” hepatocytes of carriers.  Arch Pathol. 1973;  96 (5) 327-330
  PubMedGoogle Scholar
• 9 Vázquez J J. Ground-glass hepatocytes: light and electron microscopy. Characterization of the different types.  Histol Histopathol. 1990;  5 (3) 379-386
  PubMedGoogle Scholar
• 10 Wills E J. Ground glasslike hepatocytes produced by glycogen-membrane complexes (“glycogen bodies”).  Ultrastruct Pathol. 1992;  16 (4) 491-503
  CrossrefPubMedGoogle Scholar
• 11 Callea F, de Vos R, Togni R, Tardanico R, Vanstapel M J, Desmet V J. Fibrinogen inclusions in liver cells: a new type of ground-glass hepatocyte. Immune light and electron microscopic characterization.  Histopathology. 1986;  10 (1) 65-73
  CrossrefPubMedGoogle Scholar
• 12 Bruguera M, Lamar C, Bernet M, Rodés J. Hepatic disease associated with ground-glass inclusions in hepatocytes after cyanamide therapy.  Arch Pathol Lab Med. 1986;  110 (10) 906-910
  PubMedGoogle Scholar
• 13 Moreno A, Vazquez J J, Ruizdel Arbol L, Guillen F J, Colina F. Structural hepatic changes associated with cyanamide treatment: cholangiolar proliferation, fibrosis and cirrhosis.  Liver. 1984;  4 (1) 15-21
  PubMedGoogle Scholar
• 14 De Bruyne R, Portmann B, Samyn M et al.. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.  J Hepatol. 2006;  44 (2) 407-410
  CrossrefPubMedGoogle Scholar
• 15 O'Shea A-M, Wilson G J, Ling S C, Minassian B A, Turnbull J, Cutz E. Lafora-like ground-glass inclusions in hepatocytes of pediatric patients: a report of two cases.  Pediatr Dev Pathol. 2007;  10 (5) 351-357
  CrossrefPubMedGoogle Scholar
• 16 Lefkowitch J H, Lobritto S J, Brown Jr R S et al.. Ground-glass, polyglucosan-like hepatocellular inclusions: A “new” diagnostic entity.  Gastroenterology. 2006;  131 (3) 713-718
  CrossrefPubMedGoogle Scholar
• 17 Wisell J, Boitnott J, Haas M et al.. Glycogen pseudoground glass change in hepatocytes.  Am J Surg Pathol. 2006;  30 (9) 1085-1090
  PubMedGoogle Scholar
• 18 Robitaille Y, Carpenter S, Karpati G, DiMauro S D. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.  Brain. 1980;  103 (2) 315-336
  CrossrefPubMedGoogle Scholar
• 19 Li S-C, Chen C M, Goldstein J L et al.. Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder.  J Inherit Metab Dis. 2010; January 8;  (Epub ahead of print)
  PubMedGoogle Scholar
• 20 Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.  Hum Mutat. 2009;  30 (5) 715-723
  CrossrefPubMedGoogle Scholar
• 21 Striano P, Zara F, Turnbull J et al.. Typical progression of myoclonic epilepsy of the Lafora type: a case report.  Nat Clin Pract Neurol. 2008;  4 (2) 106-111
  PubMedGoogle Scholar
• 22 Yokota T, Ishihara T, Yoshida H, Takahashi M, Uchino F, Hamanaka S. Monoclonal antibody against polyglucosan isolated from the myocardium of a patient with Lafora disease.  J Neuropathol Exp Neurol. 1988;  47 (5) 572-577
  CrossrefPubMedGoogle Scholar
• 23 Hashimoto K, Hoshii Y, Takahashi M et al.. Use of a monoclonal antibody against Lafora bodies for the immunocytochemical study of ground-glass inclusions in hepatocytes due to cyanamide.  Histopathology. 2001;  39 (1) 60-65
  CrossrefPubMedGoogle Scholar

Cristina H HajduM.D. 

Department of Pathology, New York University Langone Medical Center

560 First Avenue, TH 461, New York, NY 10016

Email: Cristina.Hajdu@nyumc.org